Montelukast Evolugen (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Evolugen, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Evolugen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Evolugen acts on the leukotriene pathway to control inflammatory airway conditions.

Asthma: reduces frequency of bronchospasm and improves long‑term control. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Dyspepsia - Nausea - Fatigue

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic granulomatosis with polyangiitis - Hepatic injury - Anaphylaxis - Neuropsychiatric events such as mood changes or suicidal thoughts

Before initiating therapy, consider the following precautions.

Liver function: assess hepatic status in patients with known liver disease. Neuropsychiatric monitoring: watch for mood alterations, depression or suicidal ideation. Pregnancy: safety category is unknown; discuss risks with a healthcare professional. Hypersensitivity: avoid in individuals with known allergy to montelukast or any tablet excipients. Drug interactions: review concomitant medications for potential interactions. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with several medicines; categorize interactions accordingly.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase plasma levels. - Phenobarbital or rifampicin (CYP inducers) can markedly reduce efficacy. - Erythromycin (CYP3A4 inhibitor) may elevate drug concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR; monitor coagulation parameters. - Theophylline: possible increase in serum levels; observe for toxicity. - Beta‑agonists: additive bronchodilatory effect; adjust dosing if needed.